Pensionfund Sabic Has $1.62 Million Stake in Cencora, Inc. (NYSE:COR)

Pensionfund Sabic grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 38.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,200 shares of the company’s stock after acquiring an additional 2,000 shares during the quarter. Pensionfund Sabic’s holdings in Cencora were worth $1,618,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Concord Wealth Partners bought a new position in Cencora during the 3rd quarter worth $30,000. SYSTM Wealth Solutions LLC bought a new position in shares of Cencora during the second quarter worth about $36,000. Ashton Thomas Securities LLC acquired a new position in shares of Cencora in the third quarter worth approximately $41,000. Fairscale Capital LLC acquired a new stake in Cencora during the 2nd quarter valued at approximately $54,000. Finally, Modus Advisors LLC acquired a new position in Cencora in the fourth quarter valued at $54,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,696 shares of company stock worth $22,862,734. 15.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

Shares of Cencora stock traded up $0.51 on Monday, reaching $229.71. 94,410 shares of the company traded hands, compared to its average volume of 831,226. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The firm has a market capitalization of $44.40 billion, a PE ratio of 30.59, a PEG ratio of 1.54 and a beta of 0.45. The company has a 50 day moving average of $237.44 and a 200 day moving average of $233.60. Cencora, Inc. has a 52 week low of $208.58 and a 52 week high of $253.27.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.96%. Cencora’s dividend payout ratio is 29.29%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on COR shares. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. UBS Group lifted their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Robert W. Baird increased their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company cut their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.